Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Current Oncology (Toronto, Ont.)
|
September 27, 2023
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023
Essa Al-Mansor, Meghan Mahoney, Maxime Chenard-Poirier, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
December 4, 2018
A prospective intervention to improve happiness and reduce burnout in oncologists
Mark Clemons, Sasha Mazzarello, Gregory Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2024
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, et al.
JAMA Oncology
|
October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M Loree, David Chan, Jennifer Lim, et al.
Breast Cancer Research and Treatment
|
April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Communications Biology
|
July 4, 2025
Neutrophil extracellular trap gene expression signatures identify prognostic and targetable signaling axes for inhibiting pancreatic tumour metastasis
Paul C McDonald, James T Topham, Shannon Awrey, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
Kyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
The Lancet. Oncology
|
November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2020
Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics
James T Topham, Joanna M Karasinska, Michael K C Lee, et al.
NPJ Precision Oncology
|
April 4, 2025
The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer
Abdul R Farooq, Amy X Zhang, Michelle Chan-Seng-Yue, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Current Oncology (Toronto, Ont.)
|
September 27, 2023
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2023
Essa Al-Mansor, Meghan Mahoney, Maxime Chenard-Poirier, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
December 4, 2018
A prospective intervention to improve happiness and reduce burnout in oncologists
Mark Clemons, Sasha Mazzarello, Gregory Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 3, 2024
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Joao Paulo Solar Vasconcelos, Nan Chen, Emma Titmuss, et al.
JAMA Oncology
|
October 3, 2024
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
Jonathan M Loree, David Chan, Jennifer Lim, et al.
Breast Cancer Research and Treatment
|
April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Communications Biology
|
July 4, 2025
Neutrophil extracellular trap gene expression signatures identify prognostic and targetable signaling axes for inhibiting pancreatic tumour metastasis
Paul C McDonald, James T Topham, Shannon Awrey, et al.
Journal of Gastrointestinal Oncology
|
January 13, 2023
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma
Kyaw L Aung, Elaine McWhirter, Stephen Welch, et al.
The Lancet. Oncology
|
November 18, 2022
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Funda Meric-Bernstam, Muralidhar Beeram, Erika Hamilton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2020
Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics
James T Topham, Joanna M Karasinska, Michael K C Lee, et al.
NPJ Precision Oncology
|
April 4, 2025
The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer
Abdul R Farooq, Amy X Zhang, Michelle Chan-Seng-Yue, et al.
Page
of 5